Inventiva announces the creation of its Scientific Advisory Board
Inventiva announces the creation of its Scientific Advisory Board
June 13, 2019
Daix (France), June 13, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the creation of its Scientific Advisory Board (SAB) to provide external scientific review and high-level advice to the Company’s management with regards to its R&D activities and product portfolio.
The SAB will cover Inventiva’s key areas of research and development with a particular focus on non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and oncology. As such, it will support Inventiva’s management regarding the preclinical and clinical aspects of the Company’s development programs and its global scientific policy, including targets, fields of research, partnerships and market access.
Chaired by Jean-Louis Junien, former Director of Inventiva’s Board of Directors and senior pharmaceutical executive with an extensive experience in the industry, the SAB will bring together the expertise of independent international scientists and clinicians in the above-mentioned fields. An additional member specialized in rare diseases to support the development of odiparcil in MPS should join the SAB shortly. The first two meetings of the SAB have already been scheduled for later this month and will focus on NASH and oncology.
Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, said: “The creation of a Scientific Advisory Board is an important step for our future development as it will help us to both accelerate and secure our discovery programmes and validate our R&D choices. The Board members will bring significant expertise, highly complementary skills and an external perspective, which will be very valuable in informing our strategy as we move forward.”
Jean-Louis Junien, Chairman of Inventiva’s Scientific Advisory Board, commented: “I am honoured to take on the role of Chairman of Inventiva’s Scientific Advisory Board, which gathers internationally recognized experts in the fields of NASH, MPS and oncology. Together, we are looking forward to accompanying Inventiva’s management in its responsibility to make important judgments related to the Company’s R&D activities and product portfolio.”
The expert members of Inventiva’s SAB are:
– Dr Sven Francque, Professor of Medicine at the Faculty of Medicine and Health Sciences at the University of Antwerp and Chairman of the Department of Gastroenterology and Hepatology. His research unit focuses on the pathophysiological mechanisms of NASH.
– Dr Manal Abdelmalek, Professor of Medicine in the Division of Gastroenterology and Hepatology at Duke University and Director of the NAFLD Clinical Research Program at Duke University. She is a standing member of the NASH Clinical Research Network (NASH CRN).
– Dr Glen Clack, Honorary Professor of Translational Medicine of the Department of Oncology and Metabolism at the University of Sheffield and previously Senior Medical Director of the Oncology Translational Medicine Unit of Astra Zeneca.
– Dr Hedy Lee Kindler, Professor of Medicine at the University of Chicago, Director of the Mesothelioma Program and Associate Vice Chair for Clinical Research. She is a past President of the International Mesothelioma Interest Group, the leading international scientific research organization dedicated to this disease.
– Dr. Gérard Zalcman, Professor of Medecine, Head of the Thoracic Oncology Department of Bichat Hospital, Paris (Paris-Diderot University), and member of the U830 INSERM laboratory, “Genetics & Biology of cancers“, at the Research Centre of the Curie Institute.
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.[/lvca_panel][lvca_panel panel_id=”panel-5bc0ba5831260″ panel_title=”Important Notice”]This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.[/lvca_panel][/lvca_accordion]